Anabolic Therapy for Osteoporosis

JAMA. 2021 Jul 27;326(4):350-351. doi: 10.1001/jama.2021.0233.

Authors

Kristine E Ensrud^{1

2}, John T Schousboe^{3

4}

Affiliations

¹ Division of Epidemiology & Community Health, Department of Medicine, University of Minnesota, Minneapolis.
² Center for Care Delivery & Outcomes Research, VA Health Care System, Minneapolis.
³ HealthPartners Institute, Bloomington, Minnesota.
⁴ Division of Health Policy & Management, University of Minnesota, Minneapolis.

PMID: 34313699
DOI: 10.1001/jama.2021.0233

No abstract available

MeSH terms

Anabolic Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use
Bone Density Conservation Agents / therapeutic use*
Calcium-Regulating Hormones and Agents / therapeutic use
Humans
Osteoporosis / drug therapy*
Parathyroid Hormone-Related Protein / therapeutic use
Teriparatide / therapeutic use

Substances

Anabolic Agents
Antibodies, Monoclonal
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents
Parathyroid Hormone-Related Protein
Teriparatide
romosozumab
abaloparatide